BKHAU
Black Hawk Acquisition Corporation
Set alert
5.24 USD 0.00 0.00%
5.24 Day range 5.24
4.02 52-week range 16.27
- YTD
- -56.19%
- 1 year
- -56.33%
- Open
- 0.00
- Prev close
- 5.24
- Mkt cap
- 20.48M
- Vol
- 110
- Avg vol
- 1.38K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.24
- High
- 5.24
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.59
- Inst. own
- 4.29%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 10.53
- 200-d avg
- 10.44
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 94.45M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 323.85K
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 10.53
- 200-day average
- 10.44
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
BKHAU Revenue — quarterly 0
BKHAU Net income — quarterly -30.70K
BKHAU EPS — quarterly -0.02
About Black Hawk Acquisition Corporation
Black Hawk Acquisition Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2023 and is based in Danville, California.
- Sector
- Financial Services
- Industry
- Shell Companies
- Country
- United States
News
- Black Hawk Acquisition Co. (NASDAQ:BKHAU) Stock Short Interest Report for October
- Black Hawk Acquisition Corporation Announces Redemption Results in Connection With Its Business Combination With Vesicor Therapeutics Inc.
- Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer
- Black Hawk Acquisition Corporation Amends Its Definitive Proxy Statement
- Black Hawk Acquisition Corporation Amends Its Definitive Proxy Statement
- Vesicor Therapeutics, Inc. and Black Hawk Acquisition Corporation Enter into a Business Combination Agreement to Create a Biotechnology Company Advancing p53-based Cancer Therapeutics Delivered Via Microvesicles
- CORRECTION: Black Hawk Acquisition Corporation Welcomes Mr. Jonathan Ginsberg to Board
- Black Hawk Acquisition Corporation Welcomes Mr. Jonathan Ginsberg to Board
- U.S. IPO Weekly Recap: Tech IPOs Pop As End Of March Approaches
- Black Hawk Acquisition Corporation Announces Closing of $69,000,000 Initial Public Offering
Your note
Sign in to keep a note on BKHAU — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Polar Asset Management Partners Inc. | 1.40% | 100,000 | 1.06M | Sep 29, 2024 |
| Yakira Capital Management, Inc. | 1.26% | 89,984 | 955.09K | Sep 29, 2024 |
| HGC Investment Management Inc. | 0.70% | 50,000 | 530.70K | Sep 29, 2024 |
| Westchester Capital Management, LLC | 0.70% | 50,000 | 530.70K | Sep 29, 2024 |
| Gabelli & Co. Investment Advisers, Inc. | 0.33% | 23,400 | 248.37K | Sep 29, 2024 |
| Gabelli Funds, LLC | 0.32% | 22,481 | 238.61K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Merger Fund, The | 0.69% | 49,391 | 524.24K | Sep 29, 2024 |
| Merger Fund Vl, The | 0.01% | 609 | 6.46K | Sep 29, 2024 |